COMP <GO>
CORZ vs BRK-B // EV/EBITDA & P/E VALUATION
Core Scientific Inc. (NASDAQ) VS. Berkshire Hathaway Inc. (Class B) (NYSE) • 15-METRIC TALLY: CORZ 2
— BRK-B 8
■ METRIC PARITY
LAST: $14.43 (-3.80%) • MKT CAP: $4.64B
valuation
—
LAST: $541.96 (+0.30%) • MKT CAP: $1.20T
valuation
9.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORZ VS. BRK-B)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORZ | BRK-B | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.47% | -46.47 | BRK-B | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 9.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.72% | 2.09% | -11.81 | BRK-B | /fcf-yield <GO> |
| Operating Margin | -60.00% | 27.80% | -87.80 | BRK-B | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 22.30% | -82.30 | BRK-B | /net-margins <GO> |
| Revenue Growth (YoY) | -37.50% | 3.93% | -41.43 | BRK-B | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | CORZ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 3.55% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.9 | 67.7 | -20.80 | BRK-B | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.61 | +0.51 | CORZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 24.3x | +4.66 | BRK-B | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.64B | $1.20T | -$1.19T | BRK-B | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORZ REV | BRK-B REV | CORZ GROSS % | BRK-B GROSS % | CORZ FCF | BRK-B FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $319.0M | $371.44B | 11.9% | — | -$450.8M | $25.04B |
| FY 2024 | $510.7M | $371.43B | 23.7% | — | -$52.1M | $11.62B |
| FY 2023 | $502.4M | $364.48B | — | — | $42.5M | $29.79B |
| FY 2022 | — | $302.02B | — | — | — | $21.89B |
| FY 2021 | — | $276.19B | — | — | — | $26.15B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORZ // BETA 1.12
BRK-B // BETA 0.61